Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PI4KB inhibitor
- Development stage
- Preclinical
- Lead developer
- Curovir
- Modality
- Small Molecules
- Administration
- Inhalation, Intranasal, Oral
01
Overview
PI4KB inhibitor is a small molecule therapeutic candidate being developed by Curovir for the treatment of various cancers. It functions by inhibiting Phosphatidylinositol 4-kinase beta (PI4KB), a host lipid kinase that plays a critical role in the synthesis of phosphatidylinositol 4-phosphate (PI4P). PI4P is a key signaling lipid and a structural component of the Golgi apparatus, where it regulates membrane trafficking and the recruitment of proteins involved in cell signaling. In oncology, PI4KB is recognized for its role in supporting the high metabolic and proliferative demands of cancer cells by facilitating efficient intracellular transport and signaling pathways. By targeting this kinase, the drug aims to disrupt the lipid signaling environment necessary for tumor growth and survival. The program is currently in the early stages of development as part of Curovir's pipeline.
- Other names
- PI4KB inhibitorPI-4KB inhibitorPI 4KB inhibitor
02
Targets
PI4KB (Phosphatidylinositol 4-kinase beta)
Beyond the preview
Go deeper on PI4KB inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PI4KB inhibitor.